Escitalopram in the Treatment of Atypical Depression: Eight Weeks Noninterventional Clinical Study in Routine Conditions of Ambulatory Practice
Authors:
Ľ. Forgáčová
Authors‘ workplace:
Psychiatrická klinika SZU, FNsP Ružinov, Bratislava
prednosta kliniky doc. MUDr. A. Rakús
Published in:
Čes. a slov. Psychiat., 104, 2008, No. 1, pp. 9-17.
Category:
Original Article
Overview
The aim of the non-interventional clinical study in routine conditions of outpatient psychiatry and neurology departments in Slovakia was to evaluate the therapeutic effect of escitalopram in patients with atypical depression and in patients with non-atypical depression. The next aim of the study was to identify clinical characteristics of atypical depression. Effect of the treatment has been evaluated by CGI-S. After eight weeks significant improvement was demonstrated in majority of patients in both atypical and non-atypical depression groupes: atypical depression – 40% normal, 39% borderline mentally ill, 18% milddly ill, 3% moderately ill. Non-atypical depression – 28% normal, 33% borderline mentally ill, 28% middly ill, 10 % moderately ill and 1% markedly ill patients. The start of therapeutic effect was faster in patients with atypical depression. Even though the results were better in patients with atypical depression, because of the worse state in baseline in patients with non-atypical depression the effect of their treatment was lower. The results of the non-interventional clinical study can be accepted as useful completion of the dates from „real world“to the spectrum of results from research concerning this common form of depression.
Key words:
atypical depression, noninterventional clinical study, escitalopram.
Sources
1. Akiskal, H.: Mood disorders. In: Kaplan, H. I., Sadock, B. J.: Synopsis of psychiatry. Willliams and Wilkins, New York, USA, 2000.
2. Akiskal, H. S., Weise, R. E.: The clinical spectrum od so-called minor depressions. Am. J. Psychother., 46, 1992, pp. 9-22.
3. Asnis, G. M., McGinn, L. K., Sanderson, W. CH.: Atypical depression: Clinical aspects and noradrenergic finction. Am. J. Psychiatry, 152, 1995, pp. 31-36.
4. Derecho, C. N., Wetzler, S., McGinn, L. K., Sanderson, W. C., Asnis, G. M.: Atypical depression among psychiatric inpatient clinical features and personality traits. J. Affect. Disord., 39, 1996, pp. 55-59.
5. DSM-IV. Diagnostic and Statistical Manual of Mental Disorders (ed 4), Washington, DC. APA, 1994.
6. Gorman, B. J. M., Korotzer, A., Su, G.: Efficacy comparison of escitalopram an citalopram in the treatment of major depressive disorder: Pooled Analysis of Placebo-Controlled Trials. CNS Spectrum, 7, 2002, (suppl. 1), pp. 40-44.
7. Henkel, V., Mergl., R., Coyne, J. C., Kohen, R. et al.: Depression with atypical feature in a sample of primare care outpatients: prevalence, specific characteristic and consequences. J. Affect. Disorder, 83, 2004, pp. 237-242.
8. Huston, P. E., Lockler, L. M.: Manic-depressive psychosis. Arch. Neurol. Psychiatry, 60, 1948, pp. 37-48.
9. Lonquist, J., Sihvo, S., Kiviruusu, O.: Moclobemide and flouxetine in atypical depression.: a double-blinde trial. J. Affect. Disord., 32, 1994, pp. 169-177.
10. Matza, L., Revicki, D., Davidson, R., Stewart, J. W.: Depression with atypical features in the National Comorbidity Survay. Arch. Gen. Psychiatry, 60, 2003, pp. 817-826.
11. McGrath, P. J., Stewart, J. W., Janal, M. N., Petkova, E., Quitkin, F. M., Klein, D. F.: A placebo controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am. J. Psychiatry, 157, 2000, pp. 344-350.
12. Mezinárodní klasifikace nemocí 10. revize. Duševní poruchy a poruchy chování. Praha, Psychiatrické centrum, 1992, 282 s. „Zprávy“ č. 102.
13. Nelson, E. B., McElroy, S. L.: Atypical depression Puzzled? How to piece together symptoms and treatments. Current Psychiatry, 2, 2003, 4, pp. 12-19.
14. Nierenberg, A. A., Alpert, J. E., Pava, J., Rosenbaum, J. F., Fava, M.: Course and treatment of atypical depression. J. Clin. Psychiatry, 59, 1998 (suppl. 18), pp. 5-9.
15. Novick, J. S., Stewart, J. W., Wisniewski, S. R., Cook, I. A., Manev, R. et al.: Clinical and demographic features of Atypical Depression in Outpatients with major depressive Disorder: Preliminary Findings From STAR*D. J. Clin. Psychiatry, 66, 2005, pp. 1002 -1011.
16. Pande, A. C., Birkett, M., Fechner-bates, S., Haskett, R. F., Greden, J. F.: Fluoxetine versus phenelzine in atypical depression. Biol. Psychiatry, 40, 1996, pp. 1017-1020.
17. Parker, G., Roy, K., Wilhelm, K., Mahli, G., Hadzi-Pavlovic, D.: Atypical depression: A Reapraisal. Am. J. Psychiatry, 159, 2002, pp. 1470-1479.
18. Paykel, E. S., Rowan, P. R., Parker, R. R., Bhat, A. V.: Response to phenelzine and amitriptyline in subtypes of outpatients depression. Arch. Gen. Psychiatry, 39, 1982, pp. 1041-1049.
19. Pollitt, J. D.: Suggestion for a physiological classification of depression. Br. J. Psychiatry, 111, 1965, pp. 489-495.
20. Quitkin, F. M., Davies C. A.: Atypical depression: current status. Curr. Opin. Psychiatry, 17, 2004, pp. 37-41.
21. Quitkin, F. M., Stewart, J. W., McGrath, P. J. et al.: Columbia atypical depression: a subgroupe of depressives with better response to MAOI than to tricyklic antidepressantns or placebo. Br. J. Psychiatry, 163, 1993 (suppl. 21), pp. 30-34.
22. Robinson, D. S., Nies, A., Ravaris, C. L. et al.: Clinical pharmacology of phenelzine. Arch. Gen. Psychiatry, 35, 1978, pp. 629-635.
23. Rush, A. J., Bose, A.: Escitalopram in clinical practice: results of an open label trial in a naturalistic setting. Depression and Anxiety, 21, 2005, pp. 26-32.
24. Sogaard, J., Lane, R., Latimer, P. et al.: A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J. Psychopharmacol., 13, 1999, 4, pp. 406-414.
25. Sullivan, P. F., Kessler, R. C., Kendler, K. S.: Latentn class analysis of lifetime depressive symptoms in the National Comorbidity Survey. Am.J. Psychiatry, 155, 1998, pp. 1398-1406.
26. Thase, M. E.: New directions in the Treatment of atypical depression. J. Clin. Psychiatry, 67, 2006, p. 18.
27. West, E. D., Dally, P. J.: Effects of iproniazide in depressive syndromes. Br. Med. J., 1, 1959, pp. 1491-1494.
Labels
Addictology Paediatric psychiatry PsychiatryArticle was published in
Czech and Slovak Psychiatry
2008 Issue 1
Most read in this issue
- Dopaminergic Mechanisms in Depression and Antidepressant Drug Effects
- Escitalopram in the Treatment of Atypical Depression: Eight Weeks Noninterventional Clinical Study in Routine Conditions of Ambulatory Practice
- Hoarding of Possessions and Animals
- Trouble with Causality: Contribution of Hallucinogens, Antidepressives and Isotretinoin to Development of Depression and the Suicidal Behaviour